COMPARISON OF LEVODOPA WITH CARBIDOPA OR BENSERAZIDE IN PARKINSONISM
Authors:
- J.K. GreenacreJGJ.K. Greenacre
- A. CoxonACA. Coxon
- A. PetrieAPA. Petrie
- J.L. ReidJRJ.L. Reid
- 1 August 1976
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 308 (7982) , 381-384
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Madopar versus SinemetEuropean Neurology, 1975
- THE RATING OF CLINICAL ANXIETYActa Psychiatrica Scandinavica, 1974
- A YEAR'S COMPARISON OF TREATMENT OF PATIENTS WITH PARKINSON'S DISEASE WITH LEVODOPA COMBINED WITH CARBIDOPA VERSUS TREATMENT WITH LEVODOPA ALONEThe Lancet, 1973
- Methyldopahydrazine as an adjunct to L‐dopa therapy in parkinsonismNeurology, 1972
- Treatment of Parkinson's disease with l-DOPA and decarboxylase inhibitorJournal of Neurology, 1972
- L-DOPA IN IDIOPATHIC PARKINSONISMThe Lancet, 1969
- Effect of various decarboxylase inhibitors on the cerebral metabolism of dihydroxyphenylalanineJournal of Pharmacy and Pharmacology, 1969
- Aromatic Amino Acids and Modification of ParkinsonismNew England Journal of Medicine, 1967
- Reduction of the central effects of tryptophan by a decarboxylase inhibitorClinical Pharmacology & Therapeutics, 1964
- Inhibition of dopa decarboxylase by the hydrazino analog of α-methyldopaBiochemical Pharmacology, 1962